1Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its rela- tionship to mortality in 116 men with breast cancer. Breast Canc- er Res Treat, 2012, 136(2) : 495-502.
2Bedognetti D, Rubagotti A, Conti G, et al. An open, random- ised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaeeomastia induced by bi- calutamide monotherapy in prostate cancer patients. Eur Urol, 2010, 57(2): 238-245.
4Van Calster B, Van Ginderachter J, Vlasselaer J, et al. Uterine and quality of life changes in postmenopausal women with an a- symptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. Meno- pause, 2011, 18(2): 224-229.
5Helmestam M, Andersson H, Stavreus-Evers A, et al. Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. Am J Pathol, 2012, 180(6) : 2527-2535.
6Staley H, Mccallum I, Bruce J. Postoperative tamoxifen for due- tal carcinoma in situ. Cochrane Database Syst Rev, 2012, 10. D7847.
7Takei H, Ohsumi S, Shimozuma K, et al. Health-related quality of life, psychological distress, and adverse events in postmenopa- usal women with breast cancer who receive tamoxifen, exemes- tane, or anastrozole as adjuvant endocrine therapy~ national sur- gical adjuvant study of breast cancer 04 (N-SAS BC 04). Breast Caneer Res Treat, 2012, 133(1) : 227-236.
8van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet, 2011, 377(9762). 321-331.
9Hurteau JA, Brady MF, Darcy KM, et al. Randomized phase Ⅲ trial of tamoxifen versus thalidomide in women with biochemical- recurrent--only epithelial ovarian, fallopian tube or primary peri- toneal carcinoma after a complete response to first-line platinum/ taxane chemotherapy with an evaluation of serum vascular endo- thelial growth factor (VEGF): a gynecologic oncology group study. Gynecol Oncol, 2010, 119(3): 444-450.
10Ashraf M, Biswas J, Majumdar S, et al. Tamoxifen use in Indian women-adverse effects revisited. Asian Pac J Cancer Prey, 2009, 10(4) : 609-612.
7Wilder JL, Shajahan S, Khattar NH, et al.Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study[J], Gynecol Oncol, 2004, 92(2): 553-558.
8Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment[J]. Gynecol Oncol, 2004, 94(2): 256-266.
9Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen[J]. Gynecol Oncol, 2003, 91:154-159.
10Cohen I, Azaria R, Bernheim J, et al. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen[J]. Cancer, 2001, 92(5): 1151 - 1155.
